Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25097540 | 1.00 | ADH1C (0.32) | ADH1CADH1AADH4SLC6A2SLC6A4 | |
| SCHEMBL23733651 | 0.82 | — | — | |
| SCHEMBL23872688 | 0.81 | SLC6A2 (0.30) | SLC6A2SLC6A4 | |
| SCHEMBL23612898 | 0.77 | SLC6A2 (0.33) | ADH1CADH1AADH4SLC6A2SLC6A4 | |
| SCHEMBL21789797 | 0.77 | PIK3CD (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL23872434 | 0.77 | PIK3CD (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL25939255 | 0.74 | DNM1 (0.31) | — | |
| SCHEMBL21789873 | 0.68 | DNM1 (0.39) | — | |
| SCHEMBL23872431 | 0.68 | — | — | |
| SCHEMBL23872439 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ADH1C 2342/4885ADH1A 2666/4885ADH4 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.